Breaking News

Pfizer Second-Quarter Adjusted EPS 58c vs. Estimate of 57c
Tweet TWEET

Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint

  Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on
                 Gilead, Pfizer, Merck, AbbVie, and LifePoint

PR Newswire

NEW YORK, July 31, 2013

NEW YORK, July 31, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Gilead
Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Merck & Co., Inc.
(NYSE: MRK), AbbVie Inc. (NYSE: ABBV), and LifePoint Hospitals, Inc. (NASDAQ:
LPNT). Today's readers may access these reports free of charge - including
full price targets, industry analysis and analyst ratings - via the links
below.

Gilead Sciences, Inc. Research Report

On July 25, 2013, Gilead Sciences, Inc. (Gilead) reported its financial
results for Q2 2013. The Company reported that its total revenues during Q2
2013 increased 15.1% YoY to $2.8 billion, with product sales increasing 14.5%
YoY to $2.7 billion, and royalty, contract, and other revenues increasing
31.2% YoY to $110.1 million. Net income attributable to Gilead was $772.6
million, or $0.46 per diluted share, in Q2 2013, compared to $711.6 million,
or $0.46 per diluted share, in Q2 2012. Further, non-GAAP net income for Q2
2013, which excludes acquisition-related, restructuring, and stock-based
compensation expense, was $839.7 million or $0.50 per diluted share, compared
to $767.3 million or $0.49 per diluted share, in Q2 2012. The Full Research
Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9898_GILD]

Pfizer Inc. Research Report

On July 25, 2013, Pfizer Inc. (Pfizer) expressed disappointment after the
Committee for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMA) re-confirmed its April 25, 2013, decision to recommend
against approval of XELJANZ (tofacitinib citrate) for the treatment of adult
patients with moderate-to-severe active rheumatoid arthritis (RA). Pfizer
stated that after a re-examination of the application as requested by the
Company, the CHMP is of the opinion that XELJANZ does not demonstrate a
favorable benefit-risk profile. Dr. Steven Romano, Senior Vice President and
the head of the Medicines Development Group for Pfizer Special Care, said,
"The clinical experience with XELJANZ to date, which includes data from
approximately 5,000 patients treated for RA, demonstrates a consistent
efficacy and safety profile across a range of patient types and a risk profile
that is familiar to rheumatologists who have experience utilizing the range of
treatments available to treat this disease. We believe that the benefit:risk
profile of XELJANZ is favorable, and we remain committed to working with the
EMA to make XELJANZ available to appropriate patients in Europe." The Full
Research Report on Pfizer Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/d702_PFE]

Merck & Co., Inc. Research Report

On July 26, 2013, Merck & Co., Inc. (Merck) issued a statement regarding the
conclusion of the EMA for CHMP review of GLP-1, or incretin-based therapies,
including sitagliptin. According to the EMA, "Investigation into GLP-1 based
diabetes therapies concluded: No new concerns for GLP-1 therapies identified
on the basis of available evidence." Michael Rosenblatt, M.D., Executive Vice
President and Chief Medical Officer of Merck, said, "We are confident in the
safety profile of sitagliptin, an important medicine to help adults with type
2 diabetes lower their blood sugar levels." He added, "The efficacy and safety
profile of sitagliptin supports its use in a wide range of adult patients with
type 2 diabetes. We will continue to monitor the safety of sitagliptin in
close collaboration with regulatory agencies and scientific experts." The Full
Research Report on Merck & Co., Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/430d_MRK]

AbbVie Inc. Research Report

On July 26, 2013, AbbVie Inc. (AbbVie) reported its financial results for Q2
2013. The Company reported that its net sales grew 4.4% YoY to $4.7 billion,
primarily driven by the continued strength of HUMIRA, as well as double-digit
growth from key products including Synthroid, Creon, Zemplar, and Duodopa. Net
earnings were $1.1 billion, or $0.66 per diluted share, in Q2 2013, compared
to $1.3 billion, or $0.80 per diluted share, in Q2 2012. The Company also
updated its diluted EPS guidance for full-year 2013 to $3.07 to $3.13 (from
$3.03 to $3.13) on an adjusted basis or $2.66 to $2.72 on a GAAP basis,
excluding $0.41 per share of intangible asset amortization expense, acquired
in-process research and development, and other specified items primarily
associated with certain separation-related costs and ongoing restructuring
activities. The Full Research Report on AbbVie Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/273c_ABBV]

LifePoint Hospitals, Inc. Research Report 

On July 26, 2013, LifePoint Hospitals, Inc. (LifePoint) reported its financial
results for Q2 2013. The Company reported that its revenues increased 8.2% YoY
to $894.9 million during Q2 2013. Net income attributable to LifePoint was
$27.4 million, or $0.57 per diluted share, in Q2 2013 compared to net income
attributable to LifePoint of $40.3 million, or $0.83 per diluted share, in Q2
2012.Commenting on the results, William F. Carpenter III, Chairman and CEO of
LifePoint, said, "We continue to position LifePoint to benefit from healthcare
reform in a challenging operating environment. Our growth and quality
initiatives drove sequential improvements in outpatient and inpatient volumes
this quarter, while our M&A program allowed us to build out our networks in
several key regions." The Full Research Report on LifePoint Hospitals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/f06d_LPNT]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    making mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Analysts' Corner

Contact: Joe Thomas: +1-310-496-8071 (North America)